CompletedPhase 2NCT04266197
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Respira Therapeutics, Inc.
- Principal Investigator
- Ed Parsley, DORespira Therapeutics
- Intervention
- Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)(combination_product)
- Enrollment
- 42 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2020 – 2025
Study locations (26)
- University of Alabama, Birmingham, Alabama, United States
- University of Arizona, Tucson, Arizona, United States
- UCLA, Los Angeles, California, United States
- University of Southern California, Los Angeles, California, United States
- UC Davis, Sacramento, California, United States
- University of California San Francisco, San Francisco, California, United States
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
- MedStar Heart and Vascular Institute, Washington D.C., District of Columbia, United States
- Augusta University, Augusta, Georgia, United States
- The University of Kansas Medical Center, Kansas City, Kansas, United States
- Norton Health, Louisville, Kentucky, United States
- Ochsner Louisiana State University Health, Shreveport, Louisiana, United States
- Tufts University, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04266197 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →